Halozyme Therapeutics HALO Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's asset turnover?
- Halozyme Therapeutics (HALO) reported asset turnover of 0.6× in Q1 2026.
- How has Halozyme Therapeutics's asset turnover changed year-over-year?
- Halozyme Therapeutics's asset turnover increased by 15.4% year-over-year, from 0.5× to 0.6×.
- What is the long-term trend for Halozyme Therapeutics's asset turnover?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's asset turnover has grown at a 5.4% compound annual growth rate (CAGR), from 0.5× to 0.6×.
- What does asset turnover mean?
- How many sales dollars the company generates from each dollar of assets.
- How do you interpret asset turnover?
- Higher turnover means a more sales-efficient asset base. Low-margin businesses (retail, distribution) compete on high turnover; high-margin ones (software, luxury) on margin.
- How does asset turnover compare across companies?
- Compare within an industry — turnover differences across sectors reflect business models, not performance.